Arvinas (ARVN) news
Recent news
Arvinas - cash position expected to fund operations into second half of 2028
AInvest Wire · Aug 4, 2026Arvinas - Co and Pfizer eligible for up to $320 mln in milestone payments and tiered royalties - SEC filing
Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) have entered into a licensing agreement with Rigel Pharmaceuticals, Inc. for the global development, manufacturing, and commercialization rights for VEPPANU™ (vepdegestrant), the first FDA-approved PROteolysis TArgeting Chimera (PROTAC)…
AInvest Wire · Jun 16, 2026Arvinas - Co and Pfizer to receive $15 mln from Rigel upon transition completion - SEC filing
AInvest Wire · Jun 16, 2026ImportantArvinas - Pfizer, and Rigel receive HSR clearance for license agreement on June 11, 2026 - SEC filing
AInvest Wire · Jun 16, 2026Rigel pays $70 mln upfront to Arvinas and Pfizer under license agreement - SEC filing
Rigel Pharmaceuticals has entered into an exclusive global license agreement with Arvinas and Pfizer for the development, manufacturing, and commercialization of VEPPANU™ (vepdegestrant), the first FDA-approved PROteolysis TArgeting Chimera (PROTAC) therapy. Under the terms of the agreement, Rigel…
AInvest Wire · Jun 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.